Skip to content
type1.science

Ypsomed mylife YpsoPump (pump)

Ypsomed

What it is

A compact, simple tubed pump with a minimal icon-driven OLED touchscreen and a small 1.6 mL (160-unit) cartridge — self-filled, or a prefilled NovoRapid cartridge in some regions. It is the hardware platform under the mylife CamAPS FX / mylife Loop closed-loop system, delivers all bolus types from a phone, and is widely available across the UK/EU but is not yet US-marketed.

Editorial review: .

Most recent recorded citation date: 2026-09-01. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.

Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence

Full sources ↓Full discussion ↓Report an issue →

Available nowRegulator-approvedpumptubeddurablephone-control

Evidence behind this assessment

Key evidence notes. Study results, product eligibility and access answer different questions.

Who was studied?
Study populations and analysis groups vary. Product age limits alone do not describe who was studied.
Benefit or performance
Reliability: Established platform with occlusion detection; an independent bench test found its accuracy was model- and rate-dependent — best at moderate-low basal rates but poorer at the very lowest (0.1 U/h) rate, where it was among the least accurate — and all pumps tended to under-deliver.[5]
Important harms and treatment burden
Read the safety discussion and original sources. A missing summary does not establish safety.
Approval and country access
Country-specific approval and access are not summarized in this record.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
Follow-up and remaining uncertainty
Read the full discussion and original sources for follow-up duration and study limitations.

This record cites company or conference reports. Those sources may describe interim findings; their source type is shown in the source list.

Editorial score: calculation and evidence

A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.

Default calculation: 60 × 20 + 70 × 20 + 55 × 20 + 78 × 15 + 48 × 10 + 64 × 15 = 6310; divide by total weight 100. Unrounded weighted result: 63.1.

Interoperability60

Anchors the commercial mylife CamAPS FX / mylife Loop AID with Dexcom G6 and FreeStyle Libre 3/3 Plus — but it is a closed commercial system with no DIY/open-source loop option described, and Dexcom G7 integration is still rolling out.[3]

Reliability70

Established platform with occlusion detection; an independent bench test found its accuracy was model- and rate-dependent — best at moderate-low basal rates but poorer at the very lowest (0.1 U/h) rate, where it was among the least accurate — and all pumps tended to under-deliver.[5]

Form factor55

One of the smallest, lightest tubed pumps (83 g; IPX8 water-resistant) but still tubed with an external infusion set — less discreet than a patch.[1]

Phone control78

The mylife App (mylife Dose) delivers standard, extended and combination boluses straight from a personal smartphone without touching the pump.[3]

Capacity48

Small 1.6 mL (160 U) cartridge — well below ~300-unit tubed rivals — but the durable body is reused and the filled reservoir lasts up to 7 days.[2]

Access & cost64

Available across the UK, EU and Australia; a durable body keeps hardware cost low, but it is not yet marketed in the US.[13]

Editor’s take

The minimalist's tubed pump: stripped-back, light, cheap to keep running, and the gateway hardware for the Cambridge (CamAPS FX) algorithm across the UK/EU. Phone bolusing is a genuine strength. The tiny 160-unit cartridge and tubing are the real trade-offs, and US availability is still pending.

The full picture

The Ypsomed mylife YpsoPump is built around a single idea: keep insulin-pump therapy as simple as possible. It is a compact, light tubed pump with a minimal, icon-driven OLED touchscreen and a deliberately stripped-back menu, marketed as "the intuitive insulin pump system."1 Outside the US it has become a quiet workhorse — the durable hardware under the Cambridge closed-loop ecosystem across the UK and Europe.

Form factor: a small tubed pump, not a patch. It is tubed — a durable pump body connected to the body by an external infusion set — rather than a tubeless patch.1 In its favour, it is one of the smallest and lightest tubed pumps available, measuring 7.8 × 4.6 × 1.6 cm and weighing about 83 g including battery and a filled cartridge, with a 4.1 × 1.6 cm OLED touchscreen and an icon-based interface.1 It runs on a single replaceable AAA (LR03) alkaline battery rather than an internal rechargeable cell — roughly 30 days per battery — and is water-resistant to IPX8 (immersion to 1 m for up to 60 minutes).1

Reservoir, cartridge and wear. The defining limitation is the small 1.6 mL (160-unit) cartridge.12 You can self-fill the mylife YpsoPump Reservoir with a rapid-acting analogue — NovoRapid, Fiasp, Humalog, Apidra or Lyumjev — and a filled reservoir is used for up to 7 days.2 In several markets a prefilled NovoRapid PumpCart is offered instead; the EMA authorised this prefilled-cartridge option (insulin aspart, 1.6 mL) in 2016, and a 130-participant handling study found prefilled cartridges roughly halved preparation time (about 2.1 vs 4.0 minutes) and improved user satisfaction versus self-filling.1116 The durable body is reused, so consumables are limited to cartridges and infusion sets.

Infusion set, occlusion detection and reliability. It uses mylife YpsoPump Orbit infusion sets (steel-needle or soft-cannula). A prospective study of these sets found 66% lasted a full 7 days, with occlusions the leading reason for early changes (19%).17 The pump detects blockages and raises an occlusion alarm, and an independent bench test of four pumps found the YpsoPump's accuracy was model- and rate-dependent: it was most accurate at moderate-low basal rates but among the least accurate at the very lowest rate (0.1 U/h, MARD 44.8%) used in children and closed-loop systems — and every pump tested tended to slightly under-deliver.18

Which CGMs, algorithms and DIY it works with. This is its strategic core. The YpsoPump is the pump inside the commercial mylife Loop / mylife CamAPS FX hybrid closed-loop system, pairing with the Dexcom G6 and FreeStyle Libre 3 / Libre 3 Plus sensors and the Cambridge (CamDiab) algorithm, approved from age 1 and in pregnancy.3 Real-world CamAPS FX data with the YpsoPump showed about 72.6% time-in-range, and a randomised trial tested the algorithm with simplified meal announcements.1920 It is a closed commercial system with no DIY/open-source loop option described, and Dexcom confirms only the G6 is currently compatible (G7 integration is rolling out).43

Phone bolusing. A real strength: the mylife App (the "mylife Dose" feature) lets users deliver standard, extended and combination boluses directly and discreetly from a personal smartphone, without interacting with the pump.3 CamAPS FX is available on both Android and, since 2025, iPhone.12

Access and cost by region. It is available across the UK, EU, Australia and New Zealand — with funded access reported in New Zealand — and the reusable body keeps hardware cost low.1321 It is not yet marketed in the US: a planned Eli Lilly partnership to sell a prefilled-cartridge version ended in 2022, and Ypsomed has been pursuing FDA clearance with a new partner.13

What's coming. The CamAPS FX algorithm received US FDA clearance on 23 May 2024 (510(k) K232603),22 and Ypsomed has been working to bring the YpsoPump to the US so the full mylife Loop can launch there.13 In the meantime, momentum outside the US continues: a 2025 iPhone rollout for CamAPS FX, expanding Dexcom G7 integration, and national funding programmes — in New Zealand, a funding-driven switch to YpsoPump-with-CamAPS-FX and Tandem cut children's average HbA1c with no severe events.12321

Fully closed-loop option. CamAPS Liberty launched on 1 September 2026 in Germany, Austria, Switzerland and Luxembourg for eligible myLoop users. This optional CamAPS FX mode removes routine meal boluses and carb counting for people with T1D aged 13+, and excludes pregnancy. The established hybrid-mode outcomes above should not be read as Liberty outcomes; its predecessor studies compared against nonautomated pump plus CGM.23

What's next for this

  • →US launch so the full mylife Loop can launch there (CamAPS FX algorithm FDA-cleared 2024; pursuing FDA clearance with a new partner)
  • →Expanding Dexcom G7 integration · rolling out
  • →iPhone rollout for CamAPS FX (2025)
  • →Broader CamAPS Liberty fully closed-loop rollout after September launch in Germany, Austria, Switzerland and Luxembourg · Italy targeted 28 October 2026

Sources

  1. [1]
    mylife YpsoPump insulin pump — product overview and technical specifications · Manufacturer

    Ypsomed (mylife Diabetescare). mylife YpsoPump insulin pump — product overview and technical specifications (tubed durable pump; 7.8 × 4.6 × 1.6 cm; 83 g with battery and filled cartridge; 4.1 × 1.6 cm OLED touchscreen, icon-based interface; AAA/LR03 battery ~30 days; IPX8 to 1 m/60 min; 1.6 mL/160 U cartridge; basal 0.00–40.0 U/h; bolus 0.1–30.0 U).

  2. [2]
    mylife YpsoPump Reservoir — capacity and compatible insulins · Manufacturer

    Ypsomed (mylife Diabetescare). mylife YpsoPump Reservoir (1.6 mL/160 U self-filled reservoir; compatible with NovoRapid, Fiasp, Humalog, Apidra and Lyumjev; filled reservoir usable up to 7 days).

  3. [3]
    YpsoPump with mylife Loop — CamAPS FX system, compatible CGMs and ages · Manufacturer

    Ypsomed (mylife Diabetescare). YpsoPump with mylife Loop (mylife CamAPS FX hybrid closed loop; YpsoPump + Dexcom G6 / FreeStyle Libre 3 / Libre 3 Plus; Cambridge/CamDiab algorithm adjusting insulin every 8–12 minutes; approved from age 1 and in pregnancy; Dexcom G7 integration in progress).

    Ypsomed (mylife Diabetescare). YpsoPump with mylife Loop / mylife App (the mylife App "mylife Dose" feature delivers standard, extended and combination boluses from a personal smartphone without interacting with the pump; integrates Dexcom G6 glucose data into the app).

  4. [4]
    Dexcom CGM systems and the mylife YpsoPump · Manufacturer

    Dexcom. Dexcom CGM systems and the mylife YpsoPump (communicate via the mylife CamAPS FX app; "Only Dexcom G6 is compatible with the mylife YpsoPump").

  5. [5]
  6. [6]
  7. [7]
  8. [8]
  9. [9]
  10. [10]
  11. [11]
    EMA Grants Marketing Authorisation of mylife YpsoPump for Use with NovoRapid PumpCart · Manufacturer · 2016-06-28

    PR Newswire / Ypsomed & Novo Nordisk. EMA Grants Marketing Authorisation of mylife YpsoPump for Use with NovoRapid PumpCart (June 2016; prefilled 1.6 mL NovoRapid/insulin aspart cartridge for the YpsoPump).

  12. [12]
    Ypsomed and CamDiab expand availability of mylife CamAPS FX on iOS · Manufacturer · 2025-06-10

    Ypsomed / CamDiab. Ypsomed and CamDiab expand availability of mylife CamAPS FX on iOS (June 10, 2025; iPhone availability across Australia and multiple European markets; supports FreeStyle Libre 3 / Libre 3 Plus and Dexcom G6).

  13. [13]
    Ypsomed seeks new partner for US insulin pump launch as Lilly quits deal · Science journalism · 2022-12-12

    Park A (MedTech Dive). Ypsomed seeks new partner for US insulin pump launch as Lilly quits deal (Dec 2022; Lilly ended its prefilled-cartridge YpsoPump partnership; YpsoPump sold in Europe since 2016 but not marketed in the US; Ypsomed pursuing FDA submission and a new US partner).

  14. [14]
  15. [15]
  16. [16]

    Gupta J, Fuchs GS, Jenkins M, et al. User Satisfaction and Insulin Pump Handling With a Prefilled Insulin Cartridge in Adults and Adolescents With Type 1 Diabetes. Journal of Diabetes Science and Technology (2019). According to PubMed — 130 participants; prefilled cartridge halved preparation time (124.4 vs 237.8 s) and improved satisfaction vs self-filled reservoir. https://pmc.ncbi.nlm.nih.gov/articles/PMC7189155/ (DOI)

  17. [17]

    Waldenmaier D, Zschornack E, Buhr A, et al. A Prospective Study of Insulin Infusion Set Use for up to 7 Days: Early Replacement Reasons and Impact on Glycemic Control. Diabetes Technology & Therapeutics (2020); 22(10):734–741. According to PubMed — YpsoPump Orbit micro (steel) and Orbit soft sets; 66% reached 7 days, occlusions the main early-replacement reason (19%). https://pubmed.ncbi.nlm.nih.gov/32167382/ (DOI)

  18. [18]

    Girardot S, Jacquemier P, Mousin F, et al. All Insulin Pumps Are Not Equivalent: A Bench Test Assessment for Several Basal Rates. Diabetes Technology & Therapeutics (2020); 22(6):476–483. According to PubMed — the Ypsomed YpsoPump was among four off-the-shelf pumps tested; all tended to under-deliver (up to −16%), with model- and basal-rate-dependent accuracy. https://pubmed.ncbi.nlm.nih.gov/32069066/ (DOI)

  19. [19]

    Newman C, Hartnell S, Wilinska M, et al. Real-World Evidence of the Cambridge Hybrid Closed-Loop App With a Novel Real-Time Continuous Glucose Monitoring System. Journal of Diabetes Science and Technology (2023); 19(1):165–168. According to PubMed — 100 users of the Cambridge app with FreeStyle Libre 3 and YpsoPump; time-in-range 72.6 ± 11.1%. https://pmc.ncbi.nlm.nih.gov/articles/PMC11688692/ (DOI)

  20. [20]

    Laesser CI, Piazza C, Schorno N, et al. Simplified meal announcement study (SMASH) using hybrid closed-loop insulin delivery in youth and young adults with type 1 diabetes: a randomised controlled two-centre crossover trial. Diabetologia (2024); 68(2):295–307. According to PubMed — mylife CamAPS FX (YpsoPump, Dexcom G6); simplified meal announcement non-inferior to carbohydrate counting (ClinicalTrials.gov NCT05481034). https://pmc.ncbi.nlm.nih.gov/articles/PMC11732900/ (DOI)

  21. [21]

    Walker M, Thomas A, Allison H, et al. Real-World Impact of a National Funding-Driven Transition Between Automated Insulin Delivery Systems in Pediatric Type 1 Diabetes. Diabetes Technology & Therapeutics (2026). According to PubMed — New Zealand PHARMAC funded Tandem t:slim X2 and Ypsomed YpsoPump; children switching (incl. YpsoPump with CamAPS FX) saw mean HbA1c fall 0.24% with no DKA or severe hypoglycaemia. https://pubmed.ncbi.nlm.nih.gov/42068144/ (DOI)

  22. [22]

    U.S. Food & Drug Administration. 510(k) Premarket Notification K232603 — CamAPS FX (CamDiab Ltd.) (cleared 23 May 2024; Interoperable Automated Glycemic Controller, 21 CFR 862.1356; for use with compatible ACE pumps and iCGMs, in type 1 diabetes from age 2). https://www.accessdata.fda.gov/cdrh_docs/pdf23/K232603.pdf

  23. [23]